Subunit Vaccines of the Future: the Need for safe, Customized and Optimized Particulate Delivery Systems

• Bloom DE , CanningD, WestonM. The value of vaccination. World Economics6(3), 15–39 (2005).
   Google Scholar
• Ehreth J . The value of vaccination: a global perspective. Vaccine21(27–30), 4105–4117 (2003).
   PubMed Web of Science ®Google Scholar
• Rappuoli R , MillerHI, FalkowS. Medicine – the intangible value of vaccination. Science297(5583), 937–940 (2002).
   PubMed Web of Science ®Google Scholar
• Rappuoli R . Bridging the knowledge gaps in vaccine design. Nat. Biotechnol.25(12), 1361–1366 (2007).
   PubMed Web of Science ®Google Scholar
• Mbow ML , De Gregorio E, Valiante NM, Rappuoli R. New adjuvants for human vaccines. Curr. Opin. Immunol.22(3), 411–416 (2010).
   PubMed Web of Science ®Google Scholar
• Reed SG , BertholetS, ColerRN, FriedeM. New horizons in adjuvants for vaccine development. Trends Immunol.30(1), 23–32 (2009).
   PubMed Web of Science ®Google Scholar
• O‘Hagan DT , De Gregorio E. The path to a successful vaccine adjuvant - the long and winding road. Drug Discov. Today14(11–12), 541–551 (2009).
   PubMed Web of Science ®Google Scholar
• O‘Hagan DT , ValianteNM. Recent advances in the discovery and delivery of vaccine adjuvants. Nat. Rev. Drug Discovery2(9), 727–735 (2003).
   PubMed Web of Science ®Google Scholar
• Guy B . The perfect mix: recent progress in adjuvant research. Nat. Rev. Microbiol.5(7), 505–517 (2007).
   PubMed Web of Science ®Google Scholar
• Dagan R , PoolmanJ, SiegristCA. Glycoconjugate vaccines and immune interference: a review. Vaccine28(34), 5513–5523 (2010).
   PubMed Web of Science ®Google Scholar
• Clements CJ , GriffithsE. The global impact of vaccines containing aluminium adjuvants. Vaccine20, S24–S33 (2002).
   PubMed Web of Science ®Google Scholar
• Lindblad EB . Aluminium adjuvants – in retrospect and prospect. Vaccine22(27–28), 3658–3668 (2004).
   PubMed Web of Science ®Google Scholar
• Hem SL , HogeneschH. Relationship between physical and chemical properties of aluminum-containing adjuvants and immunopotentiation. Expert Rev. Vaccines6(5), 685–698 (2007).
   PubMed Web of Science ®Google Scholar
• Clapp T , SiebertP, ChenD, JonesBL. Vaccines with aluminum-containing adjuvants: optimizing vaccine efficacy and thermal stability. J. Pharm. Sci.100(2), 388–401 (2011).
   PubMed Web of Science ®Google Scholar
• Marrack P , MckeeAS, MunksMW. Towards an understanding of the adjuvant action of aluminium. Nat. Rev. Immunol.9(4), 287–293 (2009).
   PubMed Web of Science ®Google Scholar
• Glenny AT , PopeCG, WaddingtonH, WallaceU. Immunological notes XVLL–XXIV. J. Pathol. Bacteriol.29(1), 31–40 (1926).
   Google Scholar
• Morefield GL , SokolovskaA, JiangDP, HogeneschH, RobinsonJP, HemSL. Role of aluminum-containing adjuvants in antigen internalization by dendritic cells in vitro. Vaccine23(13), 1588–1595 (2005).
   PubMed Web of Science ®Google Scholar
• Tritto E , MoscaF, De Gregorio E. Mechanism of action of licensed vaccine adjuvants. Vaccine27(25–26), 3331–3334 (2009).
   PubMed Web of Science ®Google Scholar
• Goto N , KatoH, MaeyamaJet al. Local tissue irritating effects and adjuvant activities of calcium phosphate and aluminium hydroxide with different physical properties. Vaccine 15(12–13), 1364–1371 (1997).
   PubMed Web of Science ®Google Scholar
• Flach TL , NgG, HariAet al. Alum interaction with dendritic cell membrane lipids is essential for its adjuvanticity. Nat. Med. 17(4), 479–487 (2011).
   PubMed Web of Science ®Google Scholar
• Nordly P , MadsenHB, NielsenHM, FogedC. Status and future prospects of lipid-based particulate delivery systems as vaccine adjuvants and their combination with immunostimulators. Expert Opin. Drug Deliv.6(7), 657–672 (2009).
   PubMed Web of Science ®Google Scholar
• O‘Hagan DT , RappuoliR, DeGE, TsaiT, DelGG. MF59 adjuvant: the best insurance against influenza strain diversity. Expert Rev. Vaccines10(4), 447–462 (2011).
   PubMed Web of Science ®Google Scholar
• Schultze V , D‘AgostoV, WackA, NovickiD, ZornJ, HennigR. Safety of MF59 (TM) adjuvant. Vaccine26(26), 3209–3222 (2008).
   PubMed Web of Science ®Google Scholar
• Ott G , BarchfeldGL, ChernoffD, RadhakrishnanR, van Hoogevest P, Van Nest G. MF59. Design and evaluation of a safe and potent adjuvant for human vaccines. Pharm. Biotechnol.6, 277–296 (1995).
   PubMedGoogle Scholar
• Banzhoff A , GaspariniR, Laghi-PasiniFet al. MF59 (R)-adjuvanted H5N1 vaccine induces immunologic memory and heterotypic antibody responses in non-elderly and elderly adults. PloS One 4(2), e4384 (2009).
   PubMed Web of Science ®Google Scholar
• Gasparini R , SchioppaF, LattanziMet al. Impact of prior or concomitant seasonal influenza vaccination on MF59-adjuvanted H1N1v vaccine (Focetria®) in adult and elderly subjects. Int. J. Clin. Pract. 64(4), 432–438 (2010).
   PubMed Web of Science ®Google Scholar
• Galli G , HancockK, HoschlerKet al. Fast rise of broadly cross-reactive antibodies after boosting long-lived human memory B cells primed by an MF59 adjuvanted prepandemic vaccine. Proc. Natl Acad. Sci. USA 106(19), 7962–7967 (2009).
   PubMed Web of Science ®Google Scholar
• Galli G , MediniD, BorgogniEet al. Adjuvanted H5N1 vaccine induces early CD4+ T cell response that predicts long-term persistence of protective antibody levels. Proc. Natl Acad. Sci. USA 106(10), 3877–3882 (2009).
   PubMed Web of Science ®Google Scholar
• Garcon N , ChomezP, Van Mechelen M. GlaxoSmithKline Adjuvant systems in vaccines: concepts, achievements and perspectives. Expert Rev. Vaccines6(5), 723–739 (2007).
   PubMed Web of Science ®Google Scholar
• Roman F , VamanT, GerlachB, MarkendorfA, GillardP, DevasterJM. Immunogenicity and safety in adults of one dose of influenza A H1N1v 2009 vaccine formulated with and without AS03A-adjuvant: preliminary report of an observer-blind, randomised trial. Vaccine28(7), 1740–1745 (2010).
   PubMed Web of Science ®Google Scholar
• Walker WT , FaustSN. Monovalent inactivated split-virion AS03-adjuvanted pandemic influenza A (H1N1) vaccine. Expert Rev. Vaccines9(12), 1385–1398 (2010).
   PubMed Web of Science ®Google Scholar
• Clark TW , PareekM, HoschlerKet al. Trial of 2009 influenza A (H1N1) monovalent MF59-adjuvanted vaccine. N. Engl. J. Med. 361(25), 2424–2435 (2009).
   PubMed Web of Science ®Google Scholar
• Caillet C , DurrieuG, JacquetAet al. Safety surveillance of influenza A(H1N1)v monovalent vaccines during the 2009–2010 mass vaccination campaign in France. Eur. J. Clin. Pharmacol. (2010).
   PubMed Web of Science ®Google Scholar
• Caillet C , PirasF, BernardMCet al. AF03-adjuvanted and non-adjuvanted pandemic influenza A (H1N1) 2009 vaccines induce strong antibody responses in seasonal influenza vaccine-primed and unprimed mice. Vaccine 28(18), 3076–3079 (2010).
   PubMed Web of Science ®Google Scholar
• Mosca F , TrittoE, MuzziAet al. Molecular and cellular signatures of human vaccine adjuvants. Proc. Natl Acad. Sci. USA 105(30), 10501–10506 (2008).
   PubMed Web of Science ®Google Scholar
• Fox CB , AndersonRC, DutillTS, GotoY, ReedSG, VedvickTS. Monitoring the effects of component structure and source on formulation stability and adjuvant activity of oil-in-water emulsions. Colloids Surf. B65(1), 98–105 (2008).
   PubMed Web of Science ®Google Scholar
• Calabro S , TortoliM, BaudnerBCet al. Vaccine adjuvants alum and MF59 induce rapid recruitment of neutrophils and monocytes that participate in antigen transport to draining lymph nodes. Vaccine 29(9), 1812–1823 (2011).
   PubMed Web of Science ®Google Scholar
• Dupuis M , MurphyTJ, HigginsDet al. Dendritic cells internalize vaccine adjuvant after intramuscular injection. Cell Immunol. 186(1), 18–27 (1998).
   PubMed Web of Science ®Google Scholar
• Ellebedy AH , LupferC, GhoneimHE, DeBeauchampJ, KannegantiTD, WebbyRJ. Inflammasome-independent role of the apoptosis-associated speck-like protein containing CARD (ASC) in the adjuvant effect of MF59. Proc. Natl Acad. Sci. USA108(7), 2927–2932 (2011).
   PubMed Web of Science ®Google Scholar
• Fourcade J , KudelaP, Andrade Filho PA et al. Immunization with analog peptide in combination with CpG and montanide expands tumor antigen-specific CD8+ T cells in melanoma patients. J. Immunother.31(8), 781–791 (2008).
   PubMed Web of Science ®Google Scholar
• Kakimi K , IsobeM, UenakaAet al. A Phase I study of vaccination with NY-ESO-1f peptide mixed with Picibanil OK-432 and Montanide ISA-51 in patients with cancers expressing the NY-ESO-1 antigen. Int. J. Cancer DOI: 10.1002/ijc.25955 (2011) (Epub ahead of print).
   Web of Science ®Google Scholar
• Diefenbach CSM , GnjaticS, SabbatiniPet al. Safety and immunogenicity study of NY-ESO-1b peptide and montanide ISA-51 vaccination of patients with epithelial ovarian cancer in high-risk first remission. Clin. Cancer Res. 14(9), 2740–2748 (2008).
   PubMed Web of Science ®Google Scholar
• Rodriguez PC , RodriguezG, GonzalezG, LageA. Clinical development and perspectives of CIMAvax EGF, cuban vaccine for non-small-cell lung cancer therapy. MEDICC Rev.12(1), 17–23 (2010).
   PubMed Web of Science ®Google Scholar
• Graham BS , McElrathMJ, KeeferMCet al. Immunization with cocktail of HIV-derived peptides in montanide ISA-51 is immunogenic, but causes sterile abscesses and unacceptable reactogenicity. PloS One 5(8), e11995 (2010).
   PubMed Web of Science ®Google Scholar
• Wu Y , EllisRD, ShafferDet al. Phase 1 trial of malaria transmission blocking vaccine candidates Pfs25 and Pvs25 formulated with montanide ISA 51. PloS One 3(7), e2636 (2008).
   PubMed Web of Science ®Google Scholar
• Schiller JT , CastellsagueX, VillaLL, HildesheimA. An update of prophylactic human papillomavirus L1 virus-like particle vaccine clinical trial results. Vaccine26(Suppl. 10), K53–K61 (2008).
   PubMed Web of Science ®Google Scholar
• Gluck R , MetcalfeIC. New technology platforms in the development of vaccines for the future. Vaccine20(Suppl. 5), B10–B16 (2002).
   PubMed Web of Science ®Google Scholar
• Christensen D , KorsholmKS, RosenkrandsI, LindenstromT, AndersenP, AggerEM. Cationic liposomes as vaccine adjuvants. Expert Rev. Vaccines6(5), 785–796 (2007).
   PubMed Web of Science ®Google Scholar
• de Bruijn I , NautaJ, GerezL, PalacheAM. The virosomal influenza vaccine Invivac: immunogenicity and tolerability compared with an adjuvanted influenza vaccine (Fluad®) in elderly subjects. Vaccine24(44–46), 6629–6631 (2006).
   PubMed Web of Science ®Google Scholar
• Bovier PA . Recent advances with a virosomal hepatitis A vaccine. Expert Opin. Biol. Therapy8(8), 1177–1185 (2008).
   PubMed Web of Science ®Google Scholar
• Campo MS , RodenRB. Papillomavirus prophylactic vaccines: established successes, new approaches. J. Virol.84(3), 1214–1220 (2010).
   PubMed Web of Science ®Google Scholar
• Fluckiger AC , LiZM, KatoRMet al. Btk/Tec kinases regulate sustained increases in intracellular Ca2+ following B-cell receptor activation. EMBO J. 17(7), 1973–1985 (1998).
   PubMed Web of Science ®Google Scholar
• Deml L , SpethC, DierichMP, WolfH, WagnerR. Recombinant HIV-1 Pr55gag virus-like particles: potent stimulators of innate and acquired immune responses. Mol. Immunol.42(2), 259–277 (2005).
   PubMed Web of Science ®Google Scholar
• Torchilin VP . Recent advances with liposomes as pharmaceutical carriers. Nat. Rev. Drug Discovery4(2), 145–160 (2005).
   PubMed Web of Science ®Google Scholar
• Frazer IH , QuinnM, NicklinJLet al. Phase 1 study of HPV16-specific immunotherapy with E6E7 fusion protein and Iscomatrix™ adjuvant in women with cervical intraepithelial neoplasia. Vaccine 23(2), 172–181 (2004).
   PubMed Web of Science ®Google Scholar
• Sun HX , XieY, YeYP. ISCOMs® and Iscomatrix™. Vaccine27(33), 4388–4401 (2009).
   PubMed Web of Science ®Google Scholar
• Nakanishi T , HayashiA, KunisawaJet al. Fusogenic liposomes efficiently deliver exogenous antigen through the cytoplasm into the MHC class I processing pathway. Eur. J. Immunol. 30(6), 1740–1747 (2000).
   PubMed Web of Science ®Google Scholar
• De Koker S , LambrechtBN, WillartMAet al. Designing polymeric particles for antigen delivery. Chem. Soc. Rev 40(1), 320–339 (2011).
   PubMed Web of Science ®Google Scholar
• Langer R , ClelandJL, HanesJ. New advances in microsphere-based single-dose vaccines. Adv. Drug Delivery Rev.28(1), 97–119 (1997).
   PubMed Web of Science ®Google Scholar
• Johansen P , GomezJMM, GanderB. Development of synthetic biodegradable microparticulate vaccines: a roller coaster story. Expert Rev. Vaccines6(4), 471–474 (2007).
   PubMed Web of Science ®Google Scholar
• Tamber H , JohansenP, MerkleHP, GanderB. Formulation aspects of biodegradable polymeric microspheres for antigen delivery. Adv. Drug Delivery Rev.57(3), 357–376 (2005).
   PubMed Web of Science ®Google Scholar
• Putney SD , BurkePA. Improving protein therapeutics with sustained-release formulations. Nat. Biotechnol.16(2), 153–157 (1998).
   PubMed Web of Science ®Google Scholar
• Johansen P , EstevezF, ZurbriggenRet al. Towards clinical testing of a single-administration tetanus vaccine based on PLA/PLGA microspheres. Vaccine 19(9–10), 1047–1054 (2000).
   PubMed Web of Science ®Google Scholar
• Feng L , QiMR, ZhouXJet al. Pharmaceutical and immunological evaluation of a single-dose hepatitis B vaccine using PLGA microspheres. J. Control. Release 112(1), 35–42 (2006).
   PubMed Web of Science ®Google Scholar
• Fischer S , SchlosserE, MuellerMet al. Concomitant delivery of a CTL-restricted peptide antigen and CpG ODN by PLGA microparticles induces cellular immune response. J. Drug Targeting 17(8), 652–661 (2009).
   PubMed Web of Science ®Google Scholar
• Kasturi SP , SkountzouI, AlbrechtRAet al. Programming the magnitude and persistence of antibody responses with innate immunity. Nature 470(7335), 543–547 (2011).
   PubMed Web of Science ®Google Scholar
• Arca HC , GunbeyazM, SenelS. Chitosan-based systems for the delivery of vaccine antigens. Expert Rev. Vaccines8(7), 937–953 (2009).
   PubMed Web of Science ®Google Scholar
• Amidi M , MastrobattistaE, JiskootW, HenninkWE. Chitosan-based delivery systems for protein therapeutics and antigens. Adv. Drug Delivery Rev.62(1), 59–82 (2010).
   PubMed Web of Science ®Google Scholar
• El-Kamary SS , PasettiMF, MendelmanPMet al. Adjuvanted intranasal norwalk virus-like particle vaccine elicits antibodies and antibody-secreting cells that express homing receptors for mucosal and peripheral lymphoid tissues. J. Infect. Dis. 202(11), 1649–1658 (2010).
   PubMed Web of Science ®Google Scholar
• Baudner BC , VerhoefJC, GiulianiMMet al. Protective immune responses to meningococcal C conjugate vaccine after intranasal immunization of mice with the LTK63 mutant plus chitosan or trimethyl chitosan chloride as novel delivery platform. J. Drug Targeting 13(8–9), 489–498 (2005).
   PubMed Web of Science ®Google Scholar
• Hagenaars N , VerheulRJ, MoorenIet al. Relationship between structure and adjuvanticity of N,N,N-trimethyl chitosan (TMC) structural variants in a nasal influenza vaccine. J. Control. Release 140(2), 126–133 (2009).
   PubMed Web of Science ®Google Scholar
• Hagenaars N , ManiaM, de Jong P et al. Role of trimethylated chitosan (TMC) in nasal residence time, local distribution and toxicity of an intranasal influenza vaccine. J. Control. Release144(1), 17–24 (2010).
   PubMed Web of Science ®Google Scholar
• Porporatto C , BiancoID, CorreaSG. Local and systemic activity of the polysaccharide chitosan at lymphoid tissues after oral administration. J. Leukocyte Biol.78(1), 62–69 (2005).
   PubMed Web of Science ®Google Scholar
• Nagamoto T , HattoriY, TakayamaK, MaitaniY. Novel chitosan particles and chitosan-coated emulsions inducing immune response via intranasal vaccine delivery. Pharm. Res.21(4), 671–674 (2004).
   PubMed Web of Science ®Google Scholar
• Slutter B , BalSM, QueIet al. Antigen-adjuvant nanoconjugates for nasal vaccination: an improvement over the use of nanoparticles? Mol. Pharmaceutics 7(6), 2207–2215 (2010).
   PubMed Web of Science ®Google Scholar
• De Koker S , De Geest BG, Singh SK et al. Polyelectrolyte microcapsules as antigen delivery vehicles to dendritic cells: uptake, processing, and cross-presentation of encapsulated antigens. Angew. Chem., Int. Ed.48(45), 8485–8489 (2009).
   PubMed Web of Science ®Google Scholar
• De Haes W , De Koker S, Pollard C et al. Polyelectrolyte capsules-containing HIV-1 p24 and poly I:C modulate dendritic cells to stimulate HIV-1-specific immune responses. Mol. Ther.18(7), 1408–1416 (2010).
   PubMed Web of Science ®Google Scholar
• Iwasaki A , MedzhitovR. Regulation of adaptive immunity by the innate immune system. Science327(5963), 291–295 (2010).
   PubMed Web of Science ®Google Scholar
• Coffman RL , SherA, SederRA. Vaccine adjuvants: putting innate immunity to work. Immunity33(4), 492–503 (2010).
   PubMed Web of Science ®Google Scholar
• Janeway CA Jr. Approaching the asymptote? Evolution and revolution in immunology. Cold Spring Harb. Symp. Quant. Biol.54Pt 1, 1–13 (1989).
   PubMedGoogle Scholar
• Vivier E , MalissenB. Innate and adaptive immunity: specificities and signaling hierarchies revisited. Nat. Rev. Immunol.6(1), 17–21 (2005).
   Google Scholar
• Medzhitov R , JanewayCA Jr. Decoding the patterns of self and nonself by the innate immune system. Science296(5566), 298–300 (2002).
   PubMed Web of Science ®Google Scholar
• Duthie MS , WindishHP, FoxCB, ReedSG. Use of defined TLR ligands as adjuvants within human vaccines. Immunol. Rev.239(1), 178–196 (2011).
   PubMed Web of Science ®Google Scholar
• Medzhitov R , Preston-HurlburtP, JanewayCA. A human homologue of the Drosophila Toll protein signals activation of adaptive immunity. Nature388(6640), 394–397 (1997).
   PubMed Web of Science ®Google Scholar
• Akira S , TakedaK. Toll-like receptor signalling. Nat. Rev. Immunol.4(7), 499–511 (2004).
   PubMed Web of Science ®Google Scholar
• Kawai T , AkiraS. The role of pattern-recognition receptors in innate immunity: update on Toll-like receptors. Nat. Immunol.11(5), 373–384 (2010).
   PubMed Web of Science ®Google Scholar
• Takeda K , AkiraS. Toll-like receptors in innate immunity. Int. Immunol.17(1), 1–14 (2005).
   PubMed Web of Science ®Google Scholar
• Medzhitov R . Toll-like receptors and innate immunity. Nat. Rev. Immunol.1(2), 135–145 (2001).
   PubMed Web of Science ®Google Scholar
• Gay NJ , GangloffM. Structure and function of Toll receptors and their ligands. Annu. Rev. Biochem.76, 141–165 (2007).
   PubMed Web of Science ®Google Scholar
• Philpott DJ , GirardinSE. The role of Toll-like receptors and Nod proteins in bacterial infection. Mol. Immunol.41(11), 1099–1108 (2004).
   PubMed Web of Science ®Google Scholar
• Krieg AM . CpG motifs in bacterial DNA and their immune effects. Annu. Rev. Immunol.20, 709–760 (2002).
   PubMed Web of Science ®Google Scholar
• Agrawal S , AgrawalA, DoughtyBet al. Cutting edge: different Toll-like receptor agonists instruct dendritic cells to induce distinct Th responses via differential modulation of extracellular signal-regulated kinase-mitogen-activated protein kinase and c-Fos. J. Immunol. 171(10), 4984–4989 (2003).
   PubMed Web of Science ®Google Scholar
• Zaks K , JordanM, GuthAet al. Efficient immunization and cross-priming by vaccine adjuvants containing TLR3 or TLR9 agonists complexed to cationic liposomes. J. Immunol. 176(12), 7335–7345 (2006).
   PubMed Web of Science ®Google Scholar
• Durand V , WongSY, ToughDF, LeBA. Shaping of adaptive immune responses to soluble proteins by TLR agonists: a role for IFN-α/β. Immunol. Cell Biol.82(6), 596–602 (2004).
   PubMed Web of Science ®Google Scholar
• Le Bon A , ToughDF. Type I interferon as a stimulus for cross-priming. Cytokine Growth Factor Rev.19(1), 33–40 (2008).
   PubMed Web of Science ®Google Scholar
• Harty JT , BevanMJ. Responses of CD8+ T cells to intracellular bacteria. Curr. Opin. Immunol.11(1), 89–93 (1999).
   PubMed Web of Science ®Google Scholar
• Casella CR , MitchellTC. Putting endotoxin to work for us: monophosphoryl lipid A as a safe and effective vaccine adjuvant. Cell. Mol. Life Sci.65(20), 3231–3240 (2008).
   PubMed Web of Science ®Google Scholar
• Garcon N . Preclinical development of AS04. Methods Mol. Biol.626, 15–27 (2010).
   PubMedGoogle Scholar
• Schwarz T . Clinical update of the AS04-Adjuvanted human Papillomavirus-16/18 cervical cancer vaccine, cervarix. Adv. Ther.26(11), 983–998 (2009).
   PubMed Web of Science ®Google Scholar
• The GlaxoSmithKline Vaccine HPV-007 Study Group: Sustained efficacy and immunogenicity of the human papillomavirus (HPV)-16/18 AS04-adjuvanted vaccine: analysis of a randomised placebo-controlled trial up to 6+4 years. The Lancet374(9706), 1975–1985 (2009).
   PubMed Web of Science ®Google Scholar
• Giannini SL , HanonE, MorisPet al. Enhanced humoral and memory B cellular immunity using HPV16/18 L1 VLP vaccine formulated with the MPL/aluminium salt combination (AS04) compared with aluminium salt only. Vaccine 24(33–34), 5937–5949 (2006).
   PubMed Web of Science ®Google Scholar
• Didierlaurent AM , MorelS, LockmanLet al. AS04, an aluminum salt- and TLR4 agonist-based adjuvant system, induces a transient localized innate immune response leading to enhanced adaptive immunity. J. Immunol. 183(10), 6186–6197 (2009).
   PubMed Web of Science ®Google Scholar
• Pichyangkul S , GettayacaminM, MillerRSet al. Pre-clinical evaluation of the malaria vaccine candidate P. falciparum MSP1(42) formulated with novel adjuvants or with alum. Vaccine 22(29–30), 3831–3840 (2004).
   PubMed Web of Science ®Google Scholar
• Brando C , WareLA, FreybergerHet al. Murine immune responses to liver-stage antigen 1 protein FMP011, a malaria vaccine candidate, delivered with adjuvant AS01B or AS02A. Infect. Immun. 75(2), 838–845 (2007).
   PubMed Web of Science ®Google Scholar
• Agger EM , RosenkrandsI, HansenJet al. Cationic liposomes formulated with synthetic mycobacterial cordfactor (CAF01): a versatile adjuvant for vaccines with different immunological requirements. PloS One 3(9), e3116 (2008).
   PubMed Web of Science ®Google Scholar
• Richards RL , RaoM, WassefNM, GlennGM, RothwellSW, AlvingCR. Liposomes containing lipid A serve as an adjuvant for induction of antibody and cytotoxic T-cell responses against RTS,S malaria antigen. Infect. Immun.66(6), 2859–2865 (1998).
   PubMed Web of Science ®Google Scholar
• Nordly P , AggerEM, AndersenP, NielsenHM, FogedC. Incorporation of the TLR4 agonist monophosphoryl lipid A into the bilayer of DDA/TDB liposomes: physico-chemical characterization and induction of CD8+ T-cell responses in vivo. Pharm. Res.28(3), 553–562 (2011).
   PubMed Web of Science ®Google Scholar
• Alexopoulou L , HoltAC, MedzhitovR, FlavellRA. Recognition of double-stranded RNA and activation of NF-κB by Toll-like receptor 3. Nature413(6857), 732–738 (2001).
   PubMed Web of Science ®Google Scholar
• Schulz O , DieboldSS, ChenMet al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 433(7028), 887–892 (2005).
   PubMed Web of Science ®Google Scholar
• Longhi MP , TrumpfhellerC, IdoyagaJet al. Dendritic cells require a systemic type I interferon response to mature and induce CD4+ Th1 immunity with poly IC as adjuvant. J. Exp. Med. 206(7), 1589–1602 (2009).
   PubMed Web of Science ®Google Scholar
• Richmond JY , HamiltonLD. Foot-and-mouth disease virus inhibition induced in mice by synthetic double-stranded RNA (polyriboinosinic and polyribocytidylic acids). Proc. Natl Acad. Sci. USA64(1), 81–86 (1969).
   PubMed Web of Science ®Google Scholar
• Field AK , TytellAA, LampsonGP, NemesMM, HillemanMR. Double-stranded polynucleotides as interferon inducers. J. Gen. Physiol.56(1), 90–96 (1970).
   PubMedGoogle Scholar
• Verdijk RM , MutisT, EsendamBet al. Polyriboinosinic polyribocytidylic acid (poly(I:C)) induces stable maturation of functionally active human dendritic cells. J. Immunol. 163(1), 57–61 (1999).
   PubMed Web of Science ®Google Scholar
• Sloat BR , CuiZ. Nasal immunization with anthrax protective antigen protein adjuvanted with polyriboinosinic-polyribocytidylic acid induced strong mucosal and systemic immunities. Pharm. Res.23(6), 1217–1226 (2006).
   PubMed Web of Science ®Google Scholar
• Trumpfheller C , CaskeyM, NchindaGet al. The microbial mimic poly IC induces durable and protective CD4+ T cell immunity together with a dendritic cell targeted vaccine. Proc. Natl Acad. Sci. USA 105(7), 2574–2579 (2008).
   PubMed Web of Science ®Google Scholar
• Fujimoto C , NakagawaY, OharaK, TakahashiH. Polyriboinosinic polyribocytidylic acid [poly(I:C)]/TLR3 signaling allows class I processing of exogenous protein and induction of HIV-specific CD8+ cytotoxic T lymphocytes. Int. Immunol.16(1), 55–63 (2004).
   PubMed Web of Science ®Google Scholar
• Salem ML , KadimaAN, ColeDJ, GillandersWE. Defining the antigen-specific T-cell response to vaccination and poly(I:C)/TLR3 signaling: evidence of enhanced primary and memory CD8 T-cell responses and antitumor immunity. J. Immunother.28(3), 220–228 (2005).
   PubMed Web of Science ®Google Scholar
• Freeman AI , Al-BussamN, O‘MalleyJA, StutzmanL, BjornssonS, CarterWA. Pharmacologic effects of polyinosinic-polycytidylic acid in man. J. Med. Virol.1(2), 79–93 (1977).
   PubMed Web of Science ®Google Scholar
• Cornell J r. CJ, Smith KA, Cornwell III GG, Burke GP, McIntyre OR. Systemic effects of intravenous polyriboinosinic-polyribocytidylic acid in man. J. Natl Cancer Inst.57(6), 1211–1216 (1976).
   PubMedGoogle Scholar
• Nordly P , RoseF, ChristensenDet al. Immunity by formulation design: Induction of high CD8+ T-cell responses by poly(I:C) incorporated into the CAF01 adjuvant via a double emulsion method. J. Control. Release 150(3), 307–317 (2011).
   PubMed Web of Science ®Google Scholar
• Fujimura T , NakagawaS, OhtaniT, ItoY, AibaS. Inhibitory effect of the polyinosinic-polycytidylic acid/cationic liposome on the progression of murine B16F10 melanoma. Eur. J. Immunol.36(12), 3371–3380 (2006).
   PubMed Web of Science ®Google Scholar
• Valmori D , SouleimanianNE, ToselloVet al. Vaccination with NY-ESO-1 protein and CpG in Montanide induces integrated antibody/Th1 responses and CD8 T cells through cross-priming. Proc. Natl Acad. Sci. USA 104(21), 8947–8952 (2007).
   PubMed Web of Science ®Google Scholar
• Karbach J , GnjaticS, BenderAet al. Tumor-reactive CD8+ T-cell responses after vaccination with NY-ESO-1 peptide, CpG 7909 and Montanide ISA-51: association with survival. Int. J. Cancer 126(4), 909–918 (2010).
   PubMed Web of Science ®Google Scholar
• Kuball J , de Boer K, Wagner E et al. Pitfalls of vaccinations with WT1-, Proteinase3-and MUC1-derived peptides in combination with MontanideISA51 and CpG7909. Cancer Immunol. Immunother.60(2), 161–171 (2011).
   PubMed Web of Science ®Google Scholar
• Sansonetti PJ . The innate signaling of dangers and the dangers of innate signaling. Nat. Immunol.7(12), 1237–1242 (2006).
   PubMed Web of Science ®Google Scholar
• Kumar H , KawaiT, AkiraS. Pathogen recognition in the innate immune response. Biochem. J.420, 1–16 (2009).
   PubMed Web of Science ®Google Scholar
• Gitlin L , BarchetW, GilfillanSet al. Essential role of mda-5 in type I IFN responses to polyriboinosinic:polyribocytidylic acid and encephalomyocarditis picornavirus. Proc. Natl Acad. Sci. USA 103(22), 8459–8464 (2006).
   PubMed Web of Science ®Google Scholar
• Kato H , TakeuchiO, SatoSet al. Differential roles of MDA5 and RIG-I helicases in the recognition of RNA viruses. Nature 441(7089), 101–105 (2006).
   PubMed Web of Science ®Google Scholar
• Kato H , TakeuchiO, Mikamo-SatohEet al. Length-dependent recognition of double-stranded ribonucleic acids by retinoic acid-inducible gene-I and melanoma differentiation-associated gene 5. J. Exp. Med. 205(7), 1601–1610 (2008).
   PubMed Web of Science ®Google Scholar
• Eisenbarth SC , ColegioOR, O‘ConnorW, SutterwalaFS, FlavellRA. Crucial role for the Nalp3 inflammasome in the immunostimulatory properties of aluminium adjuvants. Nature453(7198), 1122–1126 (2008).
   PubMed Web of Science ®Google Scholar
• Kool M , PetrilliV, DeSTet al. Cutting edge: alum adjuvant stimulates inflammatory dendritic cells through activation of the NALP3 inflammasome. J. Immunol. 181(6), 3755–3759 (2008).
   PubMed Web of Science ®Google Scholar
• Franchi L , NunezG. The Nlrp3 inflammasome is critical for aluminium hydroxide-mediated IL-1 β secretion but dispensable for adjuvant activity. Eur. J. Immunol.38(8), 2085–2089 (2008).
   PubMed Web of Science ®Google Scholar
• Werninghaus K , BabiakA, GrossOet al. Adjuvanticity of a synthetic cord factor analogue for subunit Mycobacterium tuberculosis vaccination requires FcR gamma-Syk-Card9-dependent innate immune activation. J. Exp. Med. 206(1), 89–97 (2009).
   PubMed Web of Science ®Google Scholar
• Schoenen H , BodendorferB, HitchensKet al. Cutting edge: mincle is essential for recognition and adjuvanticity of the mycobacterial cord factor and its synthetic analog trehalose-dibehenate. J. Immunol. 184(6), 2756–2760 (2010).
   PubMed Web of Science ®Google Scholar
• Matzinger P . Tolerance, danger, and the extended family. Annu. Rev. Immunol.12, 991–1045 (1994).
   PubMed Web of Science ®Google Scholar
• Kono H , RockKL. How dying cells alert the immune system to danger. Nat. Rev. Immunol.8(4), 279–289 (2008).
   PubMed Web of Science ®Google Scholar
• Medzhitov R . Origin and physiological roles of inflammation. Nature454(7203), 428–435 (2008).
   PubMed Web of Science ®Google Scholar
• Gallucci S , LolkemaM, MatzingerP. Natural adjuvants: endogenous activators of dendritic cells. Nat. Med.5(11), 1249–1255 (1999).
   PubMed Web of Science ®Google Scholar
• Matzinger P . Friendly and dangerous signals: is the tissue in control? Nat. Immunol.8(1), 11–13 (2007).
   PubMed Web of Science ®Google Scholar
• Sporri R , SousaCRE. Inflammatory mediators are insufficient for full dendritic cell activation and promote expansion of CD4+ T cell populations lacking helper function. Nat. Immunol.6(2), 163–170 (2005).
   PubMed Web of Science ®Google Scholar
• Johansen P , MohananD, Martinez-GomezJM, KundigTM, GanderB. Lympho-geographical concepts in vaccine delivery. J. Control. Release148(1), 56–62 (2010).
   PubMed Web of Science ®Google Scholar
• Mohanan D , SlutterB, Henriksen-LaceyMet al. Administration routes affect the quality of immune responses: a cross-sectional evaluation of particulate antigen-delivery systems. J. Control. Release 147(3), 342–349 (2010).
   PubMed Web of Science ®Google Scholar
• Giudice EL , CampbellJD. Needle-free vaccine delivery. Adv. Drug Delivery Rev.58(1), 68–89 (2006).
   PubMed Web of Science ®Google Scholar
• Holmgren J , CzerkinskyC. Mucosal immunity and vaccines. Nat. Med.11(4), S45–S53 (2005).
   PubMed Web of Science ®Google Scholar
• Cerutti A , ChenK, ChornyA. Immunoglobulin responses at the mucosal interface. Annu. Rev. Immunol.29, 273–293 (2011).
   PubMed Web of Science ®Google Scholar
• Mestecky J . The common mucosal immune system and current strategies for induction of immune responses in external secretions. J. Clin. Immunol.7(4), 265–276 (1987).
   PubMed Web of Science ®Google Scholar
• Gill N , WlodarskaM, FinlayBB. The future of mucosal immunology: studying an integrated system-wide organ. Nat. Immunol.11(7), 558–560 (2010).
   PubMed Web of Science ®Google Scholar
• Gallichan WS , WoolstencroftRN, GuarasciT, McCluskieMJ, DavisHL, RosenthalKL. Intranasal immunization with CpG oligodeoxynucleotides as an adjuvant dramatically increases IgA and protection against herpes simplex virus-2 in the genital tract. J. Immunol.166(5), 3451–3457 (2001).
   PubMed Web of Science ®Google Scholar
• Chen K , CeruttiA. Vaccination strategies to promote mucosal antibody responses. Immunity33(4), 479–491 (2010).
   PubMed Web of Science ®Google Scholar
• Freytag LC , ClementsJD. Mucosal adjuvants. Vaccine23(15), 1804–1813 (2005).
   PubMed Web of Science ®Google Scholar
• Chadwick S , KriegelC, AmijiM. Nanotechnology solutions for mucosal immunization. Adv. Drug Delivery Rev.62(4–5), 394–407 (2010).
   PubMed Web of Science ®Google Scholar
• Slutter B , HagenaarsN, JiskootW. Rational design of nasal vaccines. J. Drug Targeting16(1), 1–17 (2008).
   PubMed Web of Science ®Google Scholar
• Jabbal-Gill I . Nasal vaccine innovation. J. Drug Targeting18(10), 771–786 (2010).
   PubMed Web of Science ®Google Scholar
• Baudner BC , O‘HaganDT. Bioadhesive delivery systems for mucosal vaccine delivery. J. Drug Targeting18(10), 752–770 (2010).
   PubMed Web of Science ®Google Scholar
• Lu D , HickeyAJ. Pulmonary vaccine delivery. Expert Rev. Vaccines6(2), 213–226 (2007).
   PubMed Web of Science ®Google Scholar
• Blank F , StumblesP, von Garnier C. Opportunities and challenges of the pulmonary route for vaccination. Expert Opin. Drug Deliv.8(5), 547–563 (2011).
   PubMed Web of Science ®Google Scholar
• Omer SB , HiremathGS, HalseyNA. Respiratory administration of measles vaccine. Lancet375(9716), 706–708 (2010).
   PubMed Web of Science ®Google Scholar
• Patton JS , ByronPR. Inhaling medicines: delivering drugs to the body through the lungs. Nat. Rev. Drug Discovery6(1), 67–74 (2007).
   PubMed Web of Science ®Google Scholar
• Ingvarsson PT , YangM, NielsenHM, RantanenJ, FogedC. Stabilization of liposomes during drying. Expert Opin. Drug Deliv.8(3), 375–388 (2011).
   PubMed Web of Science ®Google Scholar
• Sou T , MeeusenEN, deVM, MortonDA, KaminskasLM, McIntoshMP. New developments in dry powder pulmonary vaccine delivery. Trends Biotechnol.29(4), 191–198 (2011).
   PubMed Web of Science ®Google Scholar
• Azizi A , KumarA, az-MitomaF, MesteckyJ. Enhancing oral vaccine potency by targeting intestinal M cells. PLoS Pathog.6(11), e1001147 (2010).
   PubMed Web of Science ®Google Scholar
• Mann JFS , AcevedoR, del Campo J, Perez O, Ferro VA. Delivery systems: a vaccine strategy for overcoming mucosal tolerance? Expert Rev. Vaccines8(1), 103–112 (2008).
   Web of Science ®Google Scholar
• Devriendt B , De Geest BG, Cox E. Designing oral vaccines targeting intestinal dendritic cells. Expert Opin. Drug Deliv.8(4), 467–483 (2011).
   PubMed Web of Science ®Google Scholar
• Bal SM , DingZ, vanRE, JiskootW, BouwstraJA. Advances in transcutaneous vaccine delivery: do all ways lead to Rome? J. Control. Release148(3), 266–282 (2010).
   PubMed Web of Science ®Google Scholar
• Bal SM , KruithofAC, ZwierRet al. Influence of microneedle shape on the transport of a fluorescent dye into human skin in vivo. J. Control. Release 147(2), 218–224 (2010).
   PubMed Web of Science ®Google Scholar
• Bal SM , DingZ, KerstenGF, JiskootW, BouwstraJA. Microneedle-based transcutaneous immunisation in mice with N-trimethyl chitosan adjuvanted diphtheria toxoid formulations. Pharm. Res.27(9), 1837–1847 (2010).
   PubMed Web of Science ®Google Scholar
• Bal SM , SlutterB, JiskootW, BouwstraJA. Small is beautiful: N-trimethyl chitosan-ovalbumin conjugates for microneedle-based transcutaneous immunisation. Vaccine29(23), 4025–4032 (2011).
   PubMed Web of Science ®Google Scholar
• Bal SM , SlutterB, van Riet E et al. Efficient induction of immune responses through intradermal vaccination with N-trimethyl chitosan containing antigen formulations. J. Control. Release142(3), 374–383 (2010).
   PubMed Web of Science ®Google Scholar
• Morefield GL . A rational, systematic approach for the development of vaccine formulations. AAPS J.13(2), 191–200 (2011).
   PubMed Web of Science ®Google Scholar
• Xiang SD , ScholzenA, MinigoGet al. Pathogen recognition and development of particulate vaccines: Does size matter? Methods 40(1), 1–9 (2006).
   PubMed Web of Science ®Google Scholar
• Foged C , BrodinB, FrokjaerS, SundbladA. Particle size and surface charge affect particle uptake by human dendritic cells in an in vitro model. Int. J. Pharm.298(2), 315–322 (2005).
   PubMed Web of Science ®Google Scholar
• Kersten GF , CrommelinDJ. Liposomes and ISCOMs. Vaccine21(9–10), 915–920 (2003).
   PubMed Web of Science ®Google Scholar
• Oyewumi MO , KumarA, CuiZ. Nano-microparticles as immune adjuvants: correlating particle sizes and the resultant immune responses. Expert Rev. Vaccines9(9), 1095–1107 (2010).
   PubMed Web of Science ®Google Scholar
• Bachmann MF , JenningsGT. Vaccine delivery: a matter of size, geometry, kinetics and molecular patterns. Nat. Rev. Immunol.10(11), 787–796 (2010).
   PubMed Web of Science ®Google Scholar
• Kovacsovics-Bankowski M , ClarkK, BenacerrafB, RockKL. Efficient major histocompatibility complex class I presentation of exogenous antigen upon phagocytosis by macrophages. Proc. Natl Acad. Sci. USA90(11), 4942–4946 (1993).
   PubMed Web of Science ®Google Scholar
• Reis e Sousa C , StahlPD, AustynJM. Phagocytosis of antigens by Langerhans cells in vitro. J. Exp. Med.178(2), 509–519 (1993).
   PubMed Web of Science ®Google Scholar
• Watts C . Antigen processing in the endocytic compartment. Curr. Opin. Immunol.13(1), 26–31 (2001).
   PubMed Web of Science ®Google Scholar
• Yewdell JW . Designing CD8+ T cell vaccines: it‘s not rocket science (yet). Curr. Opin. Immunol.22(3), 402–410 (2010).
   PubMed Web of Science ®Google Scholar
• Reise Sousa C , GermainRN. Major histocompatibility complex class I presentation of peptides derived from soluble exogenous antigen by a subset of cells engaged in phagocytosis. J. Exp. Med.182(3), 841–851 (1995).
   PubMed Web of Science ®Google Scholar
• Kovacsovics-Bankowski M , RockKL. A phagosome-to-cytosol pathway for exogenous antigens presented on MHC class I molecules. Science267(5195), 243–246 (1995).
   PubMed Web of Science ®Google Scholar
• Oussoren C , StormG. Liposomes to target the lymphatics by subcutaneous administration. Adv. Drug Delivery Rev.50(1–2), 143–156 (2001).
   PubMed Web of Science ®Google Scholar
• Swartz MA . The physiology of the lymphatic system. Adv. Drug Delivery Rev.50(1–2), 3–20 (2001).
   PubMed Web of Science ®Google Scholar
• Manolova V , FlaceA, BauerM, SchwarzK, SaudanP, BachmannMF. Nanoparticles target distinct dendritic cell populations according to their size. Eur. J. Immunol.38(5), 1404–1413 (2008).
   PubMed Web of Science ®Google Scholar
• Vos Q , LeesA, WuZQ, SnapperCM, MondJJ. B-cell activation by T-cell-independent type 2 antigens as an integral part of the humoral immune response to pathogenic microorganisms. Immunol. Rev.176, 154–170 (2000).
   PubMed Web of Science ®Google Scholar
• Rosenberg AS . Effects of protein aggregates: an immunologic perspective. AAPS J.8(3), E501–E507 (2006).
   PubMed Web of Science ®Google Scholar
• Steinman RM , BonifazL, FujiiSet al. The innate functions of dendritic cells in peripheral lymphoid tissues. Adv. Exp. Med. Biol. 560, 83–97 (2005).
   PubMed Web of Science ®Google Scholar
• den Haan JM , LeharSM, BevanMJ. CD8(+) but not CD8(-) dendritic cells cross-prime cytotoxic T cells in vivo. J. Exp. Med.192(12), 1685–1696 (2000).
   PubMed Web of Science ®Google Scholar
• Cella M , JarrossayD, FacchettiFet al. Plasmacytoid monocytes migrate to inflamed lymph nodes and produce large amounts of type I interferon. Nat. Med. 5(8), 919–923 (1999).
   PubMed Web of Science ®Google Scholar
• Villadangos JA , SchnorrerP. Intrinsic and cooperative antigen-presenting functions of dendritic-cell subsets in vivo. Nat. Rev. Immunol.7(7), 543–555 (2007).
   PubMed Web of Science ®Google Scholar
• Fifis T , GamvrellisA, Crimeen-IrwinBet al. Size-dependent immunogenicity: Therapeutic and protective properties of nano-vaccines against tumors. J. Immunol. 173(5), 3148–3154 (2004).
   PubMed Web of Science ®Google Scholar
• Korsholm KS , AggerEM, FogedCet al. The adjuvant mechanism of cationic dimethyldioctadecylammonium liposomes. Immunology 121(2), 216–226 (2007).
   PubMed Web of Science ®Google Scholar
• Foged C , ArigitaC, SundbladA, JiskootW, StormG, FrokjaerS. Interaction of dendritic cells with antigen-containing liposomes: effect of bilayer composition. Vaccine22(15–16), 1903–1913 (2004).
   PubMed Web of Science ®Google Scholar
• Thiele L , Rothen-RutishauserB, JilekS, Wunderli-AllenspachH, MerkleHP, WalterE. Evaluation of particle uptake in human blood monocyte-derived cells in vitro. Does phagocytosis activity of dendritic cells measure up with macrophages? J. Control. Release76(1–2), 59–71 (2001).
   PubMed Web of Science ®Google Scholar
• Walter E , DreherD, KokMet al. Hydrophilic poly(DL-lactide-co-glycolide) microspheres for the delivery of DNA to human-derived macrophages and dendritic cells. J. Control. Release 76(1–2), 149–168 (2001).
   PubMed Web of Science ®Google Scholar
• Kidane A , GuimondP, Rob Ju Tc et al. Effects of cellulose derivatives and poly(ethylene oxide)-poly(propylene oxide) tri-block copolymers (Pluronic surfactants) on the properties of alginate based microspheres and their interactions with phagocytic cells. J. Control. Release85(1–3), 181–189 (2002).
   PubMed Web of Science ®Google Scholar
• Thomas CM , RawatA, Hope-WeeksLJ, AhsanF. Aerosolized PLA and PLGA nanoparticles enhance humoral, mucosal and cytokine responses to hepatitis B vaccine. Mol. Pharm. (2010).
   Google Scholar
• Singh J , PanditS, BramwellVW, AlparHO. Diphtheria toxoid loaded poly-([ε]-caprolactone) nanoparticles as mucosal vaccine delivery systems. Methods38(2), 96–105 (2006).
   PubMed Web of Science ®Google Scholar
• Seong SY , MatzingerP. Hydrophobicity: an ancient damage-associated molecular pattern that initiates innate immune responses. Nat. Rev. Immunol.4(6), 469–478 (2004).
   PubMed Web of Science ®Google Scholar
• Champion JA , MitragotriS. Role of target geometry in phagocytosis. Proc. Natl Acad. Sci. USA103(13), 4930–4934 (2006).
   PubMed Web of Science ®Google Scholar
• World Health Organization. Manual for production and control of vaccines – tetanous toxoid. Geneva: World Health Organization (1977)
   Google Scholar
• Hansen B , SokolovskaA, HogeneschH, HemSL. Relationship between the strength of antigen adsorption to an aluminum-containing adjuvant and the immune response. Vaccine25(36), 6618–6624 (2007).
   PubMed Web of Science ®Google Scholar
• Romero MI , ShiY, HogeneschH, HemSL. Potentiation of the immune response to non-adsorbed antigens by aluminum-containing adjuvants. Vaccine25(5), 825–833 (2007).
   PubMed Web of Science ®Google Scholar
• Jorgensen L , WoodGK, RosenkrandsI, PetersenC, ChristensenD. Protein adsorption and displacement at lipid layers determined by total internal reflection fluorescence (TIRF). J. Liposome Res.19(2), 99–104 (2009).
   PubMed Web of Science ®Google Scholar
• Jones LS , PeekLJ, PowerJ, MarkhamA, YazzieB, MiddaughCR. Effects of adsorption to aluminum salt adjuvants on the structure and stability of model protein antigens. J. Biol. Chem.280(14), 13406–13414 (2005).
   PubMed Web of Science ®Google Scholar
• Jemmerson R , MargoliashE. Topographic antigenic determinants on cytochrome c. Immunoadsorbent separation of the rabbit antibody populations directed against horse cytochrome c. J. Biol. Chem.254(24), 12706–12716 (1979).
   PubMedGoogle Scholar
• Thai R , MoineG, DesmadrilMet al. Antigen stability controls antigen presentation. J. Biol. Chem. 279(48), 50257–50266 (2004).
   PubMed Web of Science ®Google Scholar
• Podda A . The adjuvanted influenza vaccines with novel adjuvants: experience with the MF59-adjuvanted vaccine. Vaccine19(17–19), 2673–2680 (2001).
   PubMed Web of Science ®Google Scholar
• Pearse MJ , DraneD. Iscomatrix adjuvant for antigen delivery. Adv. Drug Delivery Rev.57(3), 465–474 (2005).
   PubMed Web of Science ®Google Scholar

Websites

• World Health Organization. The top 10 causes of death (2008). www.who.int/mediacentre/factsheets/fs310/en/index.html
   Google Scholar
• European Medicines Agency. Guideline on adjuvants in vaccines for human use (2005). www.ema.europa.eu/docs/en_GB/document_library/Scientific_guideline/2009/09/WC500003809.pdf
   Google Scholar